Climb Bio (CLYM) Non-Current Assets (2020 - 2026)
Climb Bio's (CLYM) quarterly Non-Current Assets came in at $39.0 million in Q1 2026, down 61.21% YoY from $100.5 million in Q1 2025, and down 37.04% on a QoQ basis from $61.9 million in Q4 2025.
Climb Bio (CLYM) Non-Current Assets (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Non-Current Assets data on file, last reported at $39.0 million in Q1 2026.
- Quarterly Non-Current Assets fell 61.21% year-over-year to $39.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $297.2 million (up 58.61% YoY) and the FY2025 annual result came in at $61.9 million, down 0.67% from the prior year.
- Non-Current Assets fell to $39.0 million in Q1 2026, from $61.9 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $105.0 million in Q2 2025 to a low of $21000.0 in Q2 2024.
- A 5-year average of $32.0 million and a median of $17.0 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets slumped 98.97% — and 2025, when it surged 499909.52%.
- Tracing CLYM's Non-Current Assets over 5 years: stood at $599000.0 in 2022, then plunged by 64.27% to $214000.0 in 2023, then surged by 29019.16% to $62.3 million in 2024, then dropped by 0.67% to $61.9 million in 2025, then slumped by 37.04% to $39.0 million in 2026.
- The last three Non-Current Assets figures came in at $39.0 million (Q1 2026), $61.9 million (Q4 2025), and $91.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | 59.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.66 Mn |
| Mar 31, 2026 | 38.97 Mn |
| Dec 31, 2025 | 61.90 Mn |
| Sep 30, 2025 | 91.34 Mn |
| Jun 30, 2025 | 105.00 Mn |
| Mar 31, 2025 | 100.46 Mn |
| Dec 31, 2024 | 62.32 Mn |
| Sep 30, 2024 | 24.59 Mn |
| Jun 30, 2024 | 21,000.00 |
| Mar 31, 2024 | 111,000.00 |
| Dec 31, 2023 | 214,000.00 |
| Sep 30, 2023 | 301,000.00 |
| Jun 30, 2023 | 2.03 Mn |
| Mar 31, 2023 | 1.91 Mn |
| Dec 31, 2022 | 599,000.00 |
| Sep 30, 2022 | 7.69 Mn |
| Jun 30, 2022 | 17.03 Mn |
| Mar 31, 2022 | 29.14 Mn |
| Dec 31, 2021 | 24.99 Mn |
| Sep 30, 2021 | 23.62 Mn |